Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human ...

AUSTIN - Cassava Sciences, Inc. (NASDAQ:SAVA), currently valued at $84.54 million and trading at $1.75 per share, announced Monday that its investigational drug simufilam reduced seizure frequency ...

Cassava Sciences (SAVA) announced that the Company presented a poster at the TSC International Research Conference held June 26-28, 2025 in ...

Cassava Sciences Shares Lower Premarket on $40 Million Penalty to Settle Doctored Data Claims Global News Select Sep 27, 2024, 3:48:00 AM ...

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate ...

INmune Bio's ATM offering raises $19M ahead of Phase II results, but disappointing data and dilution signal risks. Read here ...

Cassava's Earnings Overview Yesterday, on August 8th, Cassava Sciences reported its Q2 2024 financial results, showing a net income of $6.2 million, a significant turnaround from the $26.4 million ...

Cassava Sciences Inc receives Investment Bank Analyst Rating Update By Investing.com • Sep 06, 2022 ...

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end. The company has reported top-line data from a second phase 3 trial of the drug, which ...

Cassava Sciences is nearing a Phase 3 readout for its Alzheimer's drug, lecanemab, despite facing a scandal involving the SEC. Learn more about the latest updates on donanemab and the company's ...